Combination drug
Sponsors
Zhejiang University, Bayer, Mansoura University, Asian Institute of Gastroenterology, India, Catharina Ziekenhuis Eindhoven
Conditions
AnticoagulantsB-cell Non-Hodgkin LymphomaCancerHematological MalignanciesHomologous Recombination Deficient Solid TumorsIschemiaNAFLDPancreatic Cancer
Phase 1
Clopidogrel Aspirin Therapy (CAT) Versus Apixiban Aspirin Therapy (AAT) After Lower Limb Revascularization
CompletedNCT04168398
Start: 2019-07-03End: 2021-11-03Updated: 2022-07-19
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
RecruitingNCT07220616
Start: 2026-01-16End: 2030-11-30Target: 420Updated: 2026-07-09
Phase 2
Combination of Anti-PD-1 Antibody and Chemotherapy in Metastatic Pancreatic Cancer
CompletedNCT03977272
Start: 2019-03-27End: 2022-07-01Updated: 2023-01-27
Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety
CompletedNCT04125693
Start: 2019-10-30End: 2021-02-16Updated: 2022-04-01
Niraparib and Dostarlimab in HRD Solid Tumors
NCT04983745
Start: 2021-11-29End: 2025-08-31Target: 30Updated: 2023-12-21
Phase 3
An Investigator Initiated Prospective, Four Arms Randomized Comparative Study of Efficacy and Safety of Saroglitazar, Vitamin E and Life Style Modification in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)/ Non-alcoholic Steatohepatitis (NASH)
NCT04193982
Start: 2021-01-31End: 2021-10-31Target: 250Updated: 2021-01-26
Induction Chemotherapy for Locally Recurrent Rectal Cancer
RecruitingNCT04389086
Start: 2020-11-13End: 2030-03-01Target: 364Updated: 2022-09-06